COSCIENS Biopharma Inc. Prioritizes Pipeline and Provides Corporate Update

Toronto, Ontario – December 23, 2024 – COSCIENS Biopharma Inc. (NASDAQ: CSCI) (TSX: CSCI), a leading biopharmaceutical company, released a corporate update focusing on its strategic direction towards natural-based products across cosmeceuticals, nutraceuticals, and pharmaceuticals. The company is actively streamlining its operations to support these objectives.

During a recent statement, Gilles Gagnon, President and CEO, commented, ‘Over the course of the last several months following the merger, we have taken strategic and deliberate steps to evaluate and prioritize our combined pipeline of products and programs.’ He emphasized that the company is aiming for high-value opportunities based on potential market impact.

Highlights from the Development Projects

Among the significant updates:

• Avenanthramides Tablets: The Phase 1 trial has successfully concluded, with no major side effects observed in the 72 subjects tested. The company anticipates starting the Phase 2a efficacy study in Q1 2025.
• Cosmeceuticals: COSCIENS has produced small batches of Enriched Oat Flour for use in cream formulations and has launched a new website for its JuventeDC product line.
• Nutraceuticals: The company is finalizing the Yeast Beta Glucan, targeting a Q2 2025 launch as an immune booster, and planning to introduce an Oat Beta Glucan chewable bar in Q1 2025.

Additionally, COSCIENS announced that the macimorelin DETECT-trial for Childhood Onset Growth Hormone Deficiency did not meet its primary endpoints. As a result, the company will discontinue its development but will maintain its offerings related to Adult Growth Hormone Deficiency.

Impact of the Update

The ongoing restructuring includes management changes, notably the departure of Dr. Nicola Ammer, Chief Medical Officer, expected on March 31, 2025. Gagnon stated, ‘On behalf of the entire Board and Company, we are grateful to the members of the team for their years of dedicated service.’

COSCIENS aims to leverage its advancements in natural-based health solutions to position itself as a market leader in this growing sector. A new corporate presentation focused on key development areas is slated for release in January 2025.

About COSCIENS Biopharma Inc.

COSCIENS is specialized in developing a range of products aimed at improving health and wellness through natural ingredients. For more details, visit www.cosciensbio.com.